Solvias Capabilities Update March 2026: Analytical Services

Christopher Hepler, Site Head of Solvias’ RTP Center of Excellence for Cell and Gene Therapy, introduces Solvias as a trusted, end-to-end analytical partner for the entire drug development journey. With over 25 years of experience, a global footprint, and deep scientific and regulatory expertise, Solvias supports clients from early research through commercial release. In this presentation, Hepler outlines the company’s capabilities across small molecules, biologics, and advanced modalities, including cell and gene therapies. He highlights Solvias’ robust infrastructure, global network, and strong quality track record, alongside core services such as method development, impurity testing, microbiology, and stability studies. The session also explores specialized expertise in biologics, viral safety using next-generation sequencing, and cutting-edge solutions for gene editing and cell-based therapies, positioning Solvias as a comprehensive, reliable partner for complex pharmaceutical development needs.